A multicenter, open-label, 2-stage, phase II study of single-agent obatoclax mesylate administered for three consecutive days every 2 weeks to older patients with previously untreated acute myeloid leukemia (AML).

Trial Profile

A multicenter, open-label, 2-stage, phase II study of single-agent obatoclax mesylate administered for three consecutive days every 2 weeks to older patients with previously untreated acute myeloid leukemia (AML).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2010

At a glance

  • Drugs Obatoclax (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Gemin X Pharmaceuticals
  • Most Recent Events

    • 16 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 09 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top